Join us for a discussion of patents, patent rights, limitations of patents, and alternatives for protection, from utility to Plant Patents and PVP. Additionally, the panel will delve into deposit requirements (availability to 3rd parties and timing of deposit), data- quality, scope (written description/enablement), and the dynamics for Plant Patent-Flexibility and data quality requirements, and patent enforcement.
We’ll cover where the power to regulate/enforce gets vested, and through which agency/agencies, how cannabis becomes legalized: whether through legislation, ballot measures, or litigation, and the COVID Impact: what an “essential” designation means for cannabis as a driver of international economic development.
With a new Administration and Congress, changes in personnel at FDA and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50state?
This panel seeks to get to the bottom of the IFR and what it means for the hemp CBD industry currently and in the future. We may also touch on the intersection of USDA and FDA authority to regulate hemp-derived CBD products.